文献速递外周动脉疾病

肝素涂层与标准移植物用于外周动脉疾病旁路手术的成本效果评价:随机对照试验平行研究

Cost-Effectiveness Evaluation of Heparin Coated Versus Standard Graft for Bypass Surgery in Peripheral Artery Disease Alongside a Randomised Controlled Trial.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2018-04-02

基于斯堪的纳维亚Propaten试验丹麦部分431例拟行股-股或股-腘旁路手术患者,随机接受肝素涂层或标准聚四氟乙烯移植物并随访5年。意向治疗分析显示两组在医疗成本、生命年和质量调整生命年上无统计学显著差异;每QALY平均成本估计为10792欧元,在每QALY支付意愿阈值40000欧元下总体成本效果概率为62%,严重肢体缺血亚组因成本节约(每QALY成本<0欧元)升至89%。结论认为肝素涂层移植物总体似乎具有成本效果,但应注意到间歇性跛行与严重肢体缺血间的异质性;跛行最佳选择仍不确定,严重肢体缺血应使用肝素涂层移植物。

要点

  • 意向治疗分析显示两组医疗成本、生命年和QALY差异无统计学显著。
  • 每QALY平均成本估计为10792欧元。
  • 每QALY支付意愿阈值40000欧元下总体成本效果概率62%,严重肢体缺血亚组89%。

核心结论

  • 在进一步证据出现前,肝素涂层移植物总体似乎较标准移植物具有成本效果,但应注意间歇性跛行与严重肢体缺血间的显著异质性。
  • 间歇性跛行的最佳选择仍不确定,严重肢体缺血应使用肝素涂层移植物。

研究设计与样本

  • 成本效果评价与斯堪的纳维亚Propaten试验丹麦部分平行开展,431例拟行股-股或股-腘旁路手术患者随机分配至肝素涂层或标准聚四氟乙烯移植物并随访5年。
  • 基于意向治疗原则,以算术均值及自助法95%置信区间分析医疗成本(2015年欧元)、生命年和质量调整生命年差异。

主要发现

  • 随机分组间在成本、生命年获得或QALY获得上均未观察到统计学显著差异。
  • 每QALY平均成本估计为10792欧元。
  • 每QALY支付意愿阈值40000欧元下,总体成本效果概率估计为62%。
  • 严重肢体缺血患者因成本节约(每QALY成本<0欧元),该亚组成本效果概率升至89%。

关键数值与推荐

  • 每QALY平均成本估计为10792欧元。
  • 每QALY支付意愿阈值40000欧元下总体成本效果概率为62%。
  • 严重肢体缺血亚组每QALY成本<0欧元,成本效果概率为89%。

临床怎么用

  • 作者认为严重肢体缺血应使用肝素涂层移植物。
  • 作者指出间歇性跛行的最佳选择仍不确定。

局限性

  • 原文指出间歇性跛行与严重肢体缺血之间存在重要异质性。
  • 原文结论称在进一步证据出现前,肝素涂层移植物总体似乎具有成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE/BACKGROUND: Heparin coating has recently been shown to reduce the risk of graft failure in arterial revascularisation, at least transiently. The aim of this study was to assess the cost-effectiveness of heparin coated versus standard polytetrafluoroethylene grafts for bypass surgery in peripheral artery disease from a long-term healthcare system perspective. METHODS: Cost-effectiveness evaluation was conducted alongside the Danish part of the Scandinavian Propaten trial in which 431 patients planned for femoro-femoral or femoro-popliteal bypass surgery were randomised to either type of graft and followed for 5 years. Based on the intention to treat principle, the differences in healthcare costs (general practice, prescription medication, hospital admission, rehabilitation, and long-term care in 2015 Euros), life years (LYs), and quality adjusted life years (QALYs) were analysed as arithmetic means with bootstrapped 95% confidence intervals. Cost-effectiveness acceptability curves were used to illustrate the probability of cost-effectiveness for a range of threshold values of willingness to pay (WTP). RESULTS: No statistically significant differences between the randomisation groups were observed for costs or gains of LYs or QALYs. The average cost per QALY was estimated at €10,792. For a WTP threshold of €40,000 per QALY, the overall probability of cost-effectiveness was estimated at 62%, but owing to cost savings in patients with critical ischaemia (cost per QALY <€0), it increased to 89% for this subgroup. CONCLUSION: Until further evidence, heparin coated grafts appear overall, to be cost-effective over standard grafts, but important heterogeneity between claudication and critical ischaemia should be noted. While the optimal choice for claudication remains uncertain, heparin coated grafts should be used for critical ischaemia.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Villemoes MK, Lindholt JS, Houlind KC, et al. Cost-Effectiveness Evaluation of Heparin Coated Versus Standard Graft for Bypass Surgery in Peripheral Artery Disease Alongside a Randomised Controlled Trial. Eur J Vasc Endovasc Surg. 2018. PMID: 29622512. doi:10.1016/j.ejvs.2018.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。